Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Eur Rev Med Pharmacol Sci ; 24(13): 7208, 2020 07.
Artículo en Inglés | MEDLINE | ID: mdl-32706046

RESUMEN

The article "Targeting TGF-ß1 and AKT signal on growth and metastasis of anaplastic thyroid cancer cell in vivo, by Y. Li, D. Chen, F.-Y. Hao, K.-J. Zhang, published in Eur Rev Med Pharmacol Sci 2016; 20 (12): 2581-2587. PMID: 27383308" has been withdrawn from the authors. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/11013.

2.
Eur Rev Med Pharmacol Sci ; 20(12): 2581-7, 2016 06.
Artículo en Inglés | MEDLINE | ID: mdl-27383308

RESUMEN

OBJECTIVE: We have recently reported that therapies targeting TGF-ß1 signaling were effective to prevent the anaplastic thyroid cancer (ATC) cell growth, but not the invasion. Phosphatidylinositol 3-kinase (PI3K)/AKT signaling are activated in ATC and play a major role in ATC invasion. Herein, we examined the effects of targeting TGF-ß1 by shRNA in combination with pan-AKT inhibitor, MK-2206 on growth and metastasis of ATC xenografts implanted in severe combined immunodeficient mice. MATERIALS AND METHODS: 8505C cells or 8505C/shRNA cells or 8505C/TGF-ß1 shRNA cells were implanted sc in 5-week-old female nude mice. Upon establishment of palpable tumours, MK-2206 was administered at 60 mg/kg, orally, three times a week for 6 weeks. RESULTS: The results showed that TGF-ß1/shRNA alone only prevents anaplastic thyroid cancer (ATC) tumor formation, but not lung metastasis. MK-2206 alone only inhibits lung metastasis, but not tumor formation. The combined treatment with TGF-ß1/shRNA and MK-2206 led to an approximately 71% growth inhibition compared with TGF-ß1/shRNA (44%) and MK-2206 (15%). The combined treatment with TGF-ß1/shRNA and MK-2206 significantly inhibits lung metastasis. CONCLUSIONS: These findings demonstrated that targeting TGF-ß1 in combination with MK-2206 was the effective method for treatment of ATC.


Asunto(s)
Carcinoma Anaplásico de Tiroides , Factor de Crecimiento Transformador beta1/metabolismo , Animales , Femenino , Humanos , Ratones , Ratones Desnudos , Proteína Oncogénica v-akt/metabolismo , Fosfatidilinositol 3-Quinasas/metabolismo , Transducción de Señal , Carcinoma Anaplásico de Tiroides/metabolismo , Carcinoma Anaplásico de Tiroides/patología
3.
Drug Res (Stuttg) ; 65(8): 422-7, 2015 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-25368903

RESUMEN

The aim of the present study was to assess the anticancer activity of capillarisin against human osteosarcoma (HOS) cancer cells in vitro. Cell viability after capillarisin drug treatment and evaluated by MTT assay. The extent of cell death induced by capillarisin was estimated by using lactate dehydrogenase (LDH) assay. The effect of capillarisin on cell cycle phase distribution and mitochondrial membrane potential (ΛΨm) was demonstrated via flow cytometry using propidium iodide (PI) and rhodamine-123 (Rh-123) DNA-binding fluorescent dyes respectively. Fluorescence microscopy was employed to examine the morphological changes in osteosarcoma cancer cells and presence of apoptotic bodies following capillarisin treatment. The results of this study revealed that capillarisin induced dose-dependent growth inhibition of these cancer cells after 12-h of incubation. Further, capillarisin induced significant release of LDH from these cell cultures and this LDH release was much more noticeable at higher concentrations of capillarisin. Hoechst 33258 staining revealed characteristic morphological features of apoptosis triggered by capillarisin treatment. Cell cycle analysis revealed that capillarisin induced dose-dependent G0/G1-phase cell cycle arrest. Capillarisin also trigerred a progressive and dose-dependent reduction in the mitochondrial membrane potential. In conclusion, capillarisin inhibits cancer cell growth of osteosarcoma cells by inducing apoptosis accompanied with G0/G1-phase cell cycle arrest and loss in mitochondrial membrane potential.


Asunto(s)
Antineoplásicos/farmacología , Apoptosis/efectos de los fármacos , Neoplasias Óseas/tratamiento farmacológico , Puntos de Control del Ciclo Celular/efectos de los fármacos , Cromonas/farmacología , Potencial de la Membrana Mitocondrial/efectos de los fármacos , Osteosarcoma/tratamiento farmacológico , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Fase G1/efectos de los fármacos , Humanos , Fase de Descanso del Ciclo Celular/efectos de los fármacos
4.
Eur Rev Med Pharmacol Sci ; 18(18): 2648-54, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-25317799

RESUMEN

OBJECTIVE: Group IIa secretory phospholipase A2 (sPLA2 IIa) plays a role in the malignant potential of several epithelial cancers. It is overexpressed in many cancer specimens and its elevated levels are correlated with high tumor grade and metastasis. Here, we evaluate the clinical significance of sPLA2 IIa in lung adenocarcinoma and the role of sPLA2 IIa in the process of cancer cell invasion and metastasis. PATIENTS AND METHODS: Immunohistochemistry was used to investigate sPLA2 IIa in surgically resected lung adenocarcinoma of 180 patients and its correlation with survival. We overexpressed sPLA2 IIa in a lung adenocarcinoma cell line with very low sPLA2 IIa levels and investigated the in vitro and in vivo effects of sPLA2 IIa expression. RESULTS: High expression of sPLA2 IIa in lung cancer tissue was significantly associated with clinical stage, metastasis, postoperative relapse and shorter patient survival. The overexpression of sPLA2 IIa enhanced xenograft tumor growth and invasion in vitro. CONCLUSIONS: sPLA2 IIa expression can predict the clinical outcome of lung adenocarcinoma patients. sPLA2 IIa is a novel invasion-promoting gene in lung adenocarcinoma.


Asunto(s)
Adenocarcinoma/enzimología , Adenocarcinoma/patología , Biomarcadores de Tumor/biosíntesis , Progresión de la Enfermedad , Fosfolipasas A2 Grupo II/biosíntesis , Neoplasias Pulmonares/enzimología , Neoplasias Pulmonares/patología , Adenocarcinoma/cirugía , Adenocarcinoma del Pulmón , Anciano , Animales , Línea Celular Tumoral , Humanos , Neoplasias Pulmonares/cirugía , Ratones , Ratones SCID , Invasividad Neoplásica/patología , Células Tumorales Cultivadas
5.
Eur Rev Med Pharmacol Sci ; 18(14): 2038-41, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-25027344

RESUMEN

OBJECTIVES: Cluster of differentiation 24 (CD24) was overexpressed in osteosarcoma and positive CD24 expression correlates significantly with distant metastasis invasion and poor survival in osteosarcomas. We, therefore, suggested that CD24 would be a new molecular target for therapeutic strategies. In the present study, we aimed to investigate the effects of CD24 down-regulation using monoclonal antibodies (mAb) on apoptosis in osteosarcoma cells in vitro and in vivo. MATERIALS AND METHODS: Osteosarcoma MG-63 cells were treated with Anti-CD24 mAb, and the effects on growth and apoptosis were evaluated in vitro and in vivo. RESULTS: Anti-CD24 mAb could induce the apoptosis of cultured MG63 cells and anti-CD24 mAb treatment inhibited the tumor growth after cancer cell grafting and enhanced the cell apoptosis inside the tumor tissue. CONCLUSIONS: The findings showed that anti-CD24 mAb targeting therapy provides a new avenue toward treating osteosarcoma.


Asunto(s)
Anticuerpos Monoclonales/inmunología , Anticuerpos Monoclonales/farmacología , Neoplasias Óseas/tratamiento farmacológico , Antígeno CD24/inmunología , Osteosarcoma/tratamiento farmacológico , Animales , Apoptosis/efectos de los fármacos , Neoplasias Óseas/inmunología , Neoplasias Óseas/patología , Antígeno CD24/biosíntesis , Diferenciación Celular/efectos de los fármacos , Línea Celular Tumoral , Regulación hacia Abajo/efectos de los fármacos , Humanos , Ratones , Ratones Desnudos , Terapia Molecular Dirigida , Osteosarcoma/inmunología , Osteosarcoma/patología , Distribución Aleatoria , Ensayos Antitumor por Modelo de Xenoinjerto
6.
Vaccine ; 10(4): 214-6, 1992.
Artículo en Inglés | MEDLINE | ID: mdl-1348595

RESUMEN

An inactivated golden hamster kidney cell culture (GHKC) vaccine against haemorrhagic fever with renal syndrome (HFRS) has been developed in recent years. A monovalent GHKC vaccine (lot 88-17) was prepared with L99 strain of the rat-type hantavirus, adapted in suckling mouse brain, cultivated in GHKC, and inactivated with 0.025% formalin, and a preliminary trial of the vaccine was carried out in a small number of human volunteers with the approval of the Ministry of Public Health, PRC, in order to identify safety and antibody response of the vaccine. Three inoculations were made on days 0, 7 and 28 respectively, by the intramuscular route with 1 ml vaccine each time for every volunteer. No obvious side effect was observed in vaccinees within 3 days after each inoculation. All 12 vaccinees (10 received three inoculations, and two received two inoculations of the vaccine) showed positive seroconversion of IgG antibody (by IFAT and ELISA) and neutralizing antibody (by enzyme focus reduction neutralization test, EFRNT), and 10 of them were still seropositive 180 and 360 days after the first inoculation. These results suggest that this vaccine would be safe for human use, and could effectively induce IgG and neutralizing antibody responses.


Asunto(s)
Fiebre Hemorrágica con Síndrome Renal/prevención & control , Orthohantavirus/inmunología , Vacunas Virales/inmunología , Adulto , Animales , Formación de Anticuerpos , Cricetinae , Humanos , Riñón/microbiología , Mesocricetus , Ratones , Conejos , Vacunas de Productos Inactivados/inmunología
7.
Zhonghua Nei Ke Za Zhi ; 29(7): 410-1, 444-5, 1990 Jul.
Artículo en Chino | MEDLINE | ID: mdl-2282871

RESUMEN

Ten cases of syringomyelia confirmed by magnetic resonance imaging (MRI) were presented. The cavities in the spinal cord were of low signal on T1 weighted image (T1WI) and high signal on T2 weighted image (T2WI). The segments of the spinal cord with involved lesion resembled "bamboo joints" or were of "beaded" shape on sagittal section image and of "necklace" shape on cross section image. Size of the lesions in the spinal cord shown by MRI was larger than that judged by clinical symptoms. MRI can clearly show the position, size and shape of the cavities and other abnormal conditions. Results of this study show that MRI is the most useful diagnostic tool for syringomyelia. It should be emphasized that there was no dissociated impairment of pain and temperature and touch sensation in 40% of the patients and chronic spontaneous segmental pain was one of the important clinical characteristics of syringomyelia.


Asunto(s)
Siringomielia/diagnóstico , Adulto , Femenino , Humanos , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA